Lamivudin/Zidovudin (Zidovudine, Lamivudine)

Lamivudine is a nucleoside reverse transcriptase inhibitor that, after intracellular phosphorylation, mimics natural nucleosides and is incorporated into viral DNA. This incorporation halts DNA chain elongation, preventing HIV from replicating and spreading to new cells.

The specific dose of Lamivudin/Zidovudin is determined by the prescribing clinician based on the patient’s age, weight, renal function, and overall treatment plan. Healthcare providers follow established guidelines to select the appropriate regimen.

Use of Lamivudin/Zidovudin during pregnancy or while breastfeeding should only occur when the potential benefits to the mother outweigh any possible risks to the fetus or infant. Clinicians evaluate each case individually and follow local regulatory recommendations.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudin/Zidovudin combines two NRTIs, offering a convenient single‑tablet option compared with separate agents. It provides comparable viral suppression to other NRTI‑based regimens but may differ in side‑effect profiles, resistance patterns and dosing convenience relative to newer fixed‑dose combinations.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Lamivudin/Zidovudin is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically advised by a healthcare professional.

Serious risks include lactic acidosis, severe neutropenia, hepatic steatosis, hypersensitivity reactions, pancreatitis, and bone‑marrow suppression. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Individuals with known hypersensitivity to lamivudine, zidovudine, or any excipients in the tablet should avoid this medication. It is also contraindicated in patients with severe bone‑marrow suppression or those for whom the risk of mitochondrial toxicity outweighs therapeutic benefit.